The TRIUMPH-4 trial revealed a notable incidence of dysesthesia, an abnormal sensation affecting touch perception that can cause numbness, tingling, or unusual skin sensitivity
Potential risks of this treatment are elevated blood pressure, fast heart rate, restlessness, and dry mouth
They also offer an oral GLP-1 medication: Rybelsus
Information & Authors Information Published In New England Journal of Medicine Pages: 989-1002 Copyright Copyright 2021 Massachusetts Medical Society
These findings indicate that GLP-1R activation specifically inhibits GSDMD-mediated microglial pyroptosis, a finding consistently replicated in subsequent in vitro experiments (Song et al., 2022)
You have a history of severe gastrointestinal disease, pancreatitis, or gallbladder problems